Alves-Correia M, Gaspar Â, Borrego L-M, Azevedo J, Martins C, Morais-Almeida M
Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal.
Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal.
Allergol Immunopathol (Madr). 2019 Mar-Apr;47(2):133-140. doi: 10.1016/j.aller.2018.07.007. Epub 2018 Oct 25.
Cow's milk protein allergy (CMPA) is the most common food allergy in children worldwide. Some children have severe and persistent CMPA, with near-fatal reactions after exposure to trace amounts of cow's milk-proteins (CMP). Strict avoidance diet is difficult, negatively affects quality of life and represents a conservative approach. Therefore, different therapeutic strategies are necessary.
We aimed to assess long-term efficacy and safety of oral immunotherapy (OIT) in children with severe and long-lasting IgE-mediated CMPA.
The authors present four case reports of patients with CMPA who underwent CMP-OIT, that have been under long-term follow-up up to nine years. We provide information about the clinical and laboratory evaluation. Skin prick tests (SPT), specific IgE and IgG4 were performed before, during, and after OIT. Immune profile after OIT was assessed by flow cytometry (lymphocyte subsets, regulatory T and B cells).
The success rate was 100%, and all patients currently have a free diet with minimal diary ingestion of 200mL CMP or equivalent. Specific IgE levels and SPT to CMP have progressively decreased, and specific IgG4 levels have increased. CD4CD25CD127 regulatory T cells were increased after OIT.
OIT ensured a clinical tolerance state after up to nine years, confirmed by both clinical and immune profile, allowing a diet without restrictions, with high satisfaction from patients and caregivers. We emphasize that OIT should be performed only by allergy experts in the hospital setting, and that only motivated families should be enrolled, since it is essential to ensure CMP daily intake at home.
牛奶蛋白过敏(CMPA)是全球儿童中最常见的食物过敏。一些儿童患有严重且持续的CMPA,接触微量牛奶蛋白(CMP)后会出现近乎致命的反应。严格的回避饮食很困难,会对生活质量产生负面影响,是一种保守的方法。因此,需要不同的治疗策略。
我们旨在评估口服免疫疗法(OIT)对患有严重且长期IgE介导的CMPA儿童的长期疗效和安全性。
作者介绍了4例接受CMP - OIT的CMPA患者的病例报告,这些患者已接受长达9年的长期随访。我们提供了临床和实验室评估的信息。在OIT之前、期间和之后进行了皮肤点刺试验(SPT)、特异性IgE和IgG4检测。通过流式细胞术(淋巴细胞亚群、调节性T细胞和B细胞)评估OIT后的免疫谱。
成功率为100%,所有患者目前均可自由饮食,摄入的牛奶蛋白量极少,每天不超过200mL CMP或等量物。CMP的特异性IgE水平和SPT逐渐下降,特异性IgG4水平升高。OIT后CD4CD25CD127调节性T细胞增加。
OIT在长达9年的时间里确保了临床耐受状态,这在临床和免疫谱方面均得到证实,允许无限制饮食,患者和护理人员满意度高。我们强调,OIT应仅由医院环境中的过敏专家进行,并且仅应招募有积极性的家庭,因为确保在家中每日摄入CMP至关重要。